Leitlinie „Behandlung der Akne“ - AWMF

013/017 - Behandlung der Akne aktueller Stand: 02/2010
korrigierte Fassung: 10/2011
334. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone
or levonorgestrel contraceptives. Lancet. 2001; 358: 1427-9.
335. Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in
users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet
Gynaecol. 1998; 105: 890-6.
336. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk
of venous thromboembolism: national follow-up study. Bmj. 2009; 339: b2890.
337. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal
FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and
progestogen type: results of the MEGA case-control study. Bmj. 2009; 339: b2921.
338. Waldmann-Rex S, Schramm G. VTE-Risiko unter oralen Kontrazeptiva: Fundierte
Datenlage bei Belara® (2 mg CMA/0,03 mg EE). Gyne. 2009; 10: 33.
339. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing
oral contraceptive: final results from the European Active Surveillance Study on oral
contraceptives based on 142,475 women-years of observation. Contraception. 2007;
75: 344-54.
340. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of
thromboembolism in women taking ethinylestradiol/drospirenone and other oral
contraceptives. Obstet Gynecol. 2007; 110: 587-93.
341. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year
followup study. J Cutan Med Surg. 2002; 6: 541-5.
342. Shaw JC. Hormonal therapies in acne. Expert Opin Pharmacother. 2002; 3: 865-74.
343. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol. 1961; 73: 367-
70.
344. Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during
isotretinoin therapy responding to dapsone. Clin Exp Dermatol. 1997; 22: 26-7.
345. Hofer T, Itin PH. [Acne inversa: a dapsone-sensitive dermatosis]. Hautarzt. 2001; 52:
989-92.
346. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of
five patients. J Dermatolog Treat. 2006; 17: 211-3.
347. Bolz S, Jappe U, Hartschuh W. Successful treatment of perifolliculitis capitis
abscedens et suffodiens with combined isotretinoin and dapsone. J Dtsch Dermatol
Ges. 2008; 6: 44-7.
348. Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT. Inhibition of erythromycinresistant
propionibacteria on the skin of acne patients by topical erythromycin with
and without zinc. Br J Dermatol. 1994; 130: 329-36.
349. Fluhr JW, Bosch B, Gloor M, Hoffler U. In-vitro and in-vivo efficacy of zinc acetate
against propionibacteria alone and in combination with erythromycin. Zentralbl
Bakteriol. 1999; 289: 445-56.
350. Lutz GA. Zinksalze. In: Korting HC, Sterry W: Therapeutische Verfahren in der
Dermatologie: Dermatika und Kosmetika. Berlin: Blackwell, 2001: 607-14.
351. Nitzan YB, Cohen AD. Zinc in skin pathology and care. J Dermatol Treat. 2006; 17:
205-10.
Seite 127 von 136